Clinical Cardiology 1212 - Clinical Cardiology Alert - Dec 01, 2008

Target Audience:

This activity is intended for the cardiologist.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Physician Editor
Michael H. Crawford, MD
Professor of Medicine
Chief of Cardiology
University of California
San Francisco

Editorial Board Members
John P. DiMarco, MD, PhD
Professor of Medicine
Division of Cardiology
University of Virginia
Charlottesville

Jonathan Abrams, MD
Professor of Medicine
Division of Cardiology
University of New Mexico
Albuquerque

Peer Reviewer
Andrew J. Boyle, MBBS, PhD
Assistant Professor of Medicine
Interventional Cardiology
University of California
San Francisco

Peer Reviewer
Rakesh Mishra, MD
Berkeley Cardiovascular Medical Group
Berkeley, CA

Subjects:

  • Diabetes — A Benefit from Targeted Therapy with Prasugrel in ACS
  • BMS vs LIMA for Proximal LAD Lesions: 10-Year Follow-up of the SIMS Trial
  • Lower Mortality with Drug-Eluting Stents than Bare-Metal Stents
  • Bridging Anticoagulant Therapy for Mechanical Valve Patients
  • Effect of N-33 Polyunsaturated Fatty Acids in Heart Failure
  • Sudden Death After Myocardial Infarction

Objectives:

  • to present the latest information regarding diagnosis and treatment of cardiac disease
  • to discuss the pros and cons of these interventions, as well as possible complications
  • to discuss the pros, cons, and cost-effectiveness of new and traditional diagnostic tests
  • to present current data regarding outpatient care of cardiac patients

Financial Disclosure:

Clinical Cardiology Alert's physician editor, Michael H. Crawford, MD, is on the speaker's bureau for Pfizer. Editorial board member Jonathan Abrams, MD serves on the speaker's bureau for Merck, Pfizer, and Parke-Davis. Editorial board member John P. DiMarco, MD, PhD is a consultant for Novartis, and does research for Medtronic and Guidant. Author Andrew J. Boyle, MBBS, PhD reports no consultant, stockholder, speaker's bureau, or other financial relationship with any company related to this field of study.

Copyright 2008 AHC Media. All rights reserved.